IP Library › Granted Patent US 9,907,837
Granted Patent B2
US 9,907,837 · App. 14/400,299 · Granted Mar 6, 2018

Composition for preventing or treating cachexia

Inventor: Sang Jae Kim (Seoul, KR)
Assignee: GemVax & KAEL Co., Ltd.
A61K38/45A23L33/18A61K9/0019A61K38/10C12N9/1276A23V2002/00A61K38/00C12Y207/07049
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,907,837
App. No.
14/400,299
Granted
Mar 6, 2018
Kind
B2
Abstract

The present invention relates to composition for preventing or treating cachexia, and more specifically, to a composition for preventing or treating cachexia containing a peptide derived from a telomerase. The composition for preventing or treating cachexia, according to present invention, has the advantages of improving symptoms of cachexia, such as weight loss, anemia, edema, and loss of appetite, and has few side effects.

Claims (16)

1. A method for treating cachexia caused by rheumatoid arthritis comprising administering to a subject in need thereof the isolated peptide of SEQ ID NO: 1.

2. The method according to claim 1 , wherein the peptide is administered in a single dose at a concentration of 0.001 to 1 ng/kg.

3. The method according to claim 1 , wherein the peptide is administered in a single dose at a concentration of 0.01 to 0.4 ng/kg.

4. The method according to claim 1 , wherein the peptide is administered 1 to 3 times a day.

5. The method of claim 1 , wherein the peptide is administered at a daily dose of 0.001 to 1 ng/kg.

6. The method of claim 5 , wherein the peptide is administered 1 to 3 times daily.

7. A method for treating cachexia caused by rheumatoid arthritis comprising administering to a subject in need thereof a composition comprising the isolated peptide of SEQ ID NO: 1.

8. The method of claim 7 , wherein the composition is administered through oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, intramedullary, epidural, or subcutaneous routes.

9. The method of claim 7 , wherein the composition comprises 0.1 μg/mg to 1 mg/mg of isolated peptide.

10. The method of claim 7 , wherein the peptide is administered in a single dose at a concentration of 0.001 to 1 ng/kg.

11. The method of claim 7 , wherein the peptide is administered in a single dose at a concentration of 0.01 to 0.4 ng/kg.

12. The method of claim 7 , wherein the peptide is administered 1 to 3 times a day.

13. The method of claim 12 , wherein the peptide is administered at a daily dose of 0.001 to 1 ng/kg.

14. The method of claim 13 , wherein the peptide is administered 1 to 3 times daily.

15. The method of claim 7 , wherein the composition is a pharmaceutical composition.

16. The method of claim 15 , wherein the composition is formulated for injection.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2015
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 036428/0741 →
Priority Claims (4)
KR 10-2012-0050529 · May 11, 2012 · national
KR 10-2012-0050533 · May 11, 2012 · national
KR 10-2012-0071989 · Jul 2, 2012 · national
KR 10-2012-0104207 · Sep 19, 2012 · national
Continuity (1)
Related Publication 20150353903A1 · Dec 10, 2015